In contrast, ADCs, especially T-DXd, have shown encouraging results in HER2-mutated advanced lung cancer and gastroesophageal cancer that led to FDA approvals (Shitara et al., 2020; Li et al., 2022). This evidence concerns the gene ERBB2 and lung carcinoma.